Phase II study of dovitinib in patients with metastatic and/or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib.
about
Emerging Agents for the Treatment of Advanced, Imatinib-Resistant Gastrointestinal Stromal Tumors: Current Status and Future DirectionsDovitinib and erlotinib in patients with metastatic non-small cell lung cancer: A drug-drug interaction.The broad-spectrum receptor tyrosine kinase inhibitor dovitinib suppresses growth of BRAF-mutant melanoma cells in combination with other signaling pathway inhibitors.The Effect of Mutations on Drug Sensitivity and Kinase Activity of Fibroblast Growth Factor Receptors: A Combined Experimental and Theoretical Study.Pazopanib in metastatic multiply treated progressive gastrointestinal stromal tumors: feasible and efficacious.Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+, HER2- breast cancer that had progressed during or after prior endocrine therapy.Controversies in the management of gastrointestinal stromal tumors.GIST treatment options after tyrosine kinase inhibitors.Targeting platelet-derived growth factor (PDGF) signaling in gastrointestinal cancers: preclinical and clinical considerations.Investigational therapies up to Phase II which target PDGF receptors: potential anti-cancer therapeutics.Systemic therapy options for advanced gastrointestinal stromal tumors beyond first-line imatinib: a systematic review.Clinical development landscape in GIST: from novel agents that target accessory pathways to revisiting non-targeted therapies.Dovitinib (CHIR258, TKI258): structure, development and preclinical and clinical activity.Dovitinib enhances temozolomide efficacy in glioblastoma cells.Interaction potential of the multitargeted receptor tyrosine kinase inhibitor dovitinib with drug transporters and drug metabolising enzymes assessed in vitro.Dovitinib in patients with gastrointestinal stromal tumour refractory and/or intolerant to imatinib.Imaging therapy response of gastrointestinal stromal tumors (GIST) with FDG PET, CT and MRI: a systematic review.Emerging drugs for the treatment of gastrointestinal stromal tumour.New targets and therapies for gastrointestinal stromal tumors.Latest advances in adult gastrointestinal stromal tumors.A drug-drug interaction study to assess the effect of the CYP1A2 inhibitor fluvoxamine on the pharmacokinetics of dovitinib (TKI258) in patients with advanced solid tumors.Incidence, Diagnosis, and Management of QT Prolongation Induced by Cancer Therapies: A Systematic Review.Analysis of serum protein biomarkers, circulating tumor DNA, and dovitinib activity in patients with tyrosine kinase inhibitor-refractory gastrointestinal stromal tumors.Phase 2 study of dovitinib in patients with metastatic or unresectable adenoid cystic carcinoma.Contemporary Management of Metastatic Gastrointestinal Stromal Tumors: Systemic and Locoregional Approaches.
P2860
Q26799387-9028D056-054F-44B0-98AF-459A783D5A61Q33165980-E09B85A3-B252-4BEB-B3B3-116CFFE18EEBQ35597799-42B57DEA-E13A-4DAC-987A-4D60A630AE36Q35752926-4F4B65B3-2198-4D79-A1F0-6A86B83D66AEQ37131708-6BB78990-3F1C-4B9B-AFFC-8F2BDC9DA520Q37635256-B796CF8A-0DAB-47A1-9C2E-12B110D42D83Q38199797-E4DB177E-A366-4D43-B066-8C1E0B365752Q38222205-B190E7D1-BD61-4C50-B679-0D9937029A0BQ38268000-F8F84D14-01C0-4B00-8BE5-19FEF9864C20Q38323440-20CE3673-18DA-46C2-8857-861554F33A00Q38527941-02D8FD9A-CB65-4940-8BFF-662412594A45Q38925022-5162C03B-8A87-469C-845F-D52785F7A6CDQ39062384-F996C22F-57C4-4516-9BD4-01A73B60CA7DQ40214485-CD3CFFF5-4FC0-42F1-B5BA-C70F330658D7Q43084566-65F4D254-5568-4B83-9420-9A4E0C4626A6Q44640459-8A9EDE0E-E559-40F3-B269-69A7C910B885Q47097647-23C5BEA2-5168-4486-B624-0B27F1FC6E89Q47355982-7B1B1EEA-9CAA-4777-8999-0F075868FD1DQ47432725-BCDD5AE3-5DCA-4644-A843-28272DBC6EF7Q47912361-112283B8-A71A-4F39-BF02-463E35B0E975Q48366406-D38FC41A-8E61-49F5-8424-A35C8D20CE96Q49244147-E9A183C8-F5E8-4813-9931-6829D72C77B8Q53263530-67A8EB08-A61B-405A-ACEE-E6BBDBAF2B7DQ53533566-549398DB-4FD7-4A8A-9B33-1C68DF4F982FQ54863183-B09DC3A4-B035-425F-A840-C3AEE2C58147
P2860
Phase II study of dovitinib in patients with metastatic and/or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib.
description
2013 nî lūn-bûn
@nan
2013 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Phase II study of dovitinib in ...... ure of imatinib and sunitinib.
@ast
Phase II study of dovitinib in ...... ure of imatinib and sunitinib.
@en
type
label
Phase II study of dovitinib in ...... ure of imatinib and sunitinib.
@ast
Phase II study of dovitinib in ...... ure of imatinib and sunitinib.
@en
prefLabel
Phase II study of dovitinib in ...... ure of imatinib and sunitinib.
@ast
Phase II study of dovitinib in ...... ure of imatinib and sunitinib.
@en
P2093
P2860
P356
P1476
Phase II study of dovitinib in ...... ure of imatinib and sunitinib.
@en
P2093
P2860
P2888
P304
P356
10.1038/BJC.2013.594
P407
P50
P577
2013-10-01T00:00:00Z
P5875
P6179
1019262013